戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ion, we have identified for the first time a nonsteroidal agent that selectively activates beta1-cont
2 lofexor (formerly GS-9674), a small-molecule nonsteroidal agonist of farnesoid X receptor, in patient
3 gimens in patients with prior sensitivity to nonsteroidal AI and in baseline plasma from the PALOMA3
4 MBC whose disease progresses while receiving nonsteroidal AIs.
5              Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term
6 d crystal structure of the GR LBD bound to a nonsteroidal antagonist, and this article provides addit
7 igand-binding domain (GR LBD) complex with a nonsteroidal antagonist, compound 8, was determined.
8 d intracellular CYP450 on the removal of six nonsteroidal anti-inflammatories (NSAIs) by Trametes hir
9 drugs in five different classes (uricosuric, nonsteroidal anti-inflammatories, loop diuretics, angiot
10 anti-inflammatory activity compared with the nonsteroidal anti-inflammatory agent ketorolac.
11 ly symptomatic osteoarthritis managed with a nonsteroidal anti-inflammatory agent.
12 k have often included patients using aspirin/nonsteroidal anti-inflammatory agents (NSAIDs) or acid-s
13                                      Topical nonsteroidal anti-inflammatory agents (NSAIDs) proved to
14                                              Nonsteroidal anti-inflammatory agents are not associated
15 hol-related conditions), and medication use (nonsteroidal anti-inflammatory agents, corticosteroids,
16 rvations: Regional analgesia, acetaminophen, nonsteroidal anti-inflammatory agents, gabapentinoids, t
17 the relationship between early postoperative nonsteroidal anti-inflammatory drug (NSAID) administrati
18        Inhibition of PGE2 production through nonsteroidal anti-inflammatory drug (NSAID) administrati
19                                     Reported nonsteroidal anti-inflammatory drug (NSAID) allergies ma
20 l carbonic anhydrase inhibitor in 6 eyes and nonsteroidal anti-inflammatory drug (NSAID) drops in 2 e
21                                              Nonsteroidal anti-inflammatory drug (NSAID) exacerbated
22           Diclofenac sodium is a widely used nonsteroidal anti-inflammatory drug (NSAID) for relief o
23 en single nucleotide polymorphisms (SNPs) in nonsteroidal anti-inflammatory drug (NSAID) metabolism a
24                                 In eyes with nonsteroidal anti-inflammatory drug (NSAID) monotherapy
25 tive net arylation of the minimally modified nonsteroidal anti-inflammatory drug (NSAID) naproxen.
26 al prednisolone acetate (PA) alone or with a nonsteroidal anti-inflammatory drug (NSAID) or intraoper
27 y examined whether short-term use of topical nonsteroidal anti-inflammatory drug (NSAID) or steroid t
28 ng body of evidence links certain aspects of nonsteroidal anti-inflammatory drug (NSAID) pharmacology
29  K-80003, a tRXRalpha modulator derived from nonsteroidal anti-inflammatory drug (NSAID) sulindac, su
30 s between the microbiota and indomethacin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibit
31 PT; aspirin/clopidogrel, ticagrelor) but not nonsteroidal anti-inflammatory drug (NSAID) treatment wi
32 l trials have showed no relationship between nonsteroidal anti-inflammatory drug (NSAID) use and AD.
33                                              Nonsteroidal anti-inflammatory drug (NSAID) use is recom
34 ty analyses by repeating the analyses in non-nonsteroidal anti-inflammatory drug (NSAID) users (n = 3
35 (II)-phenanthroline complexes containing the nonsteroidal anti-inflammatory drug (NSAID), indomethaci
36  This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhib
37                                  Multitarget nonsteroidal anti-inflammatory drug (NSAID)-carbonic anh
38 tro test to either diagnose or differentiate nonsteroidal anti-inflammatory drug (NSAID)-exacerbated
39                                              Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated
40 landin E(2) (PGE(2) ) has been postulated in nonsteroidal anti-inflammatory drug (NSAID)-exacerbated
41                                              Nonsteroidal anti-inflammatory drug (NSAID)-induced urti
42  and anticancer evaluation of novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) hybrid mo
43  large effusion or tamponade, and failure of nonsteroidal anti-inflammatory drug [NSAID] treatment) i
44 idence of risk transformation during chronic nonsteroidal anti-inflammatory drug administration, this
45      This approach was employed to prepare a nonsteroidal anti-inflammatory drug analogue.
46 K3 channels (A237T) or by application of the nonsteroidal anti-inflammatory drug flufenamic acid (FFA
47  the fragrance component celestolide and the nonsteroidal anti-inflammatory drug ibuprofen, are descr
48 identified a context-dependent effect of the nonsteroidal anti-inflammatory drug indomethacin (IND) o
49                                Diclofenac, a nonsteroidal anti-inflammatory drug inhibiting COX-2, in
50                                 Baseline and nonsteroidal anti-inflammatory drug reaction clinical da
51                                              Nonsteroidal anti-inflammatory drug therapy was effectiv
52 ition and systemic vascular dysfunction with nonsteroidal anti-inflammatory drug usage.
53 , be physically active, not smoke, and avoid nonsteroidal anti-inflammatory drug use except aspirin p
54 s and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent color
55 ching yielded 6,088 statin user pairs, 2,886 nonsteroidal anti-inflammatory drug user pairs, 1,440 gl
56 r statin users, 1.00 (95% CI, 0.90-1.11) for nonsteroidal anti-inflammatory drug users, 0.97 (95% CI,
57 statin users, 21.3% (95% CI, 19.8-22.9%) for nonsteroidal anti-inflammatory drug users, 17.4% (95% CI
58                            Mefenamic acid, a nonsteroidal anti-inflammatory drug, has been identified
59                       Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent
60 ment goals are not met, a trial of a topical nonsteroidal anti-inflammatory drug, tramadol, or both i
61 methylation and deuteration of nimesulide, a nonsteroidal anti-inflammatory drug, were realized throu
62                                              Nonsteroidal anti-inflammatory drug-activated gene-1 (NA
63                 Some manifestations, such as nonsteroidal anti-inflammatory drug-associated angioedem
64              We examined the role of RGS4 in nonsteroidal anti-inflammatory drug-associated bronchoco
65                                              Nonsteroidal anti-inflammatory drug-exacerbated respirat
66 uished: NSAID-exacerbated cutaneous disease, nonsteroidal anti-inflammatory drug-induced urticaria/an
67 intestinal injury induced by indomethacin, a nonsteroidal anti-inflammatory drug.
68 he first time both ionization states of this nonsteroidal anti-inflammatory drug.
69                  Treatment with a potent non-nonsteroidal anti-inflammatory druglike GSM revealed a n
70  4.81-5.64), steroids (3.18; 2.99-3.39), and nonsteroidal anti-inflammatory drugs (2.37; 2.26-2.48) w
71 ocal anesthesia (31.1% vs 12.9%; P < 0.001), nonsteroidal anti-inflammatory drugs (33.5% vs 14.4%; P
72 lume, followed by topical steroids (86%) and nonsteroidal anti-inflammatory drugs (66%), and accounte
73 rent use of antihypertensive medications and nonsteroidal anti-inflammatory drugs (adjusted odds rati
74                                              Nonsteroidal anti-inflammatory drugs (e.g. aspirin, ibup
75 tions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake.
76 or alcohol consumption, co-administration of nonsteroidal anti-inflammatory drugs (NSAID) or concomit
77 mide antibiotics (7.4%), opiates (6.8%), and nonsteroidal anti-inflammatory drugs (NSAIDs) (3.5%).
78  19), NAR against aspirin (n = 12) and other nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 8), a
79 ere included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258)
80 ly to experience IOP spikes than those using nonsteroidal anti-inflammatory drugs (NSAIDs) alone (haz
81 ing acute or chronic pains or inflammations, nonsteroidal anti-inflammatory drugs (NSAIDs) also assoc
82                           Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-do
83                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) are among
84                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) are assume
85 For treatment of malignant pleural effusion, nonsteroidal anti-inflammatory drugs (NSAIDs) are avoide
86                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) are effect
87                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) are effica
88 lusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) are sparse
89                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mo
90                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mo
91 related anaphylaxis induced by LTPs requires nonsteroidal anti-inflammatory drugs (NSAIDs) as a trigg
92                       Clinical Question: Are nonsteroidal anti-inflammatory drugs (NSAIDs) associated
93                                  Are topical nonsteroidal anti-inflammatory drugs (NSAIDs) associated
94                                          Are nonsteroidal anti-inflammatory drugs (NSAIDs) associated
95                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage
96                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) cause bron
97  to aspirin (acetylsalicylic acid) and other nonsteroidal anti-inflammatory drugs (NSAIDs) constitute
98         Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) contribute
99 infarction (MI); however, concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) could pose
100  drugs such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) for mild c
101                          The role of topical nonsteroidal anti-inflammatory drugs (NSAIDs) for the re
102        Certain rapid reversible, competitive nonsteroidal anti-inflammatory drugs (NSAIDs) have been
103                                              Nonsteroidal anti-inflammatory drugs (NSAIDs) have many
104                                              Nonsteroidal anti-inflammatory drugs (NSAIDS) have recei
105                  Structural modifications of nonsteroidal anti-inflammatory drugs (NSAIDs) have succe
106 enefit the most from using aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in relatio
107                      Ion-exchange removal of nonsteroidal anti-inflammatory drugs (NSAIDs) in synthet
108           The subcellular mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) induce apo
109                     Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associa
110                          Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) is of grea
111                   We evaluated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on surviva
112         We sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on T-cell
113 escribe the effect of routine use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on the inc
114 s document for hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) proposed b
115 ND & AIMS: Use of aspirin and/or non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduces th
116           Small intestinal damage induced by nonsteroidal anti-inflammatory drugs (NSAIDs) remains an
117                                      Topical nonsteroidal anti-inflammatory drugs (NSAIDs) significan
118 have demonstrated the remarkable efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ib
119                   Targeting of COX-1/2 using nonsteroidal anti-inflammatory drugs (NSAIDs) such as th
120                                     Although nonsteroidal anti-inflammatory drugs (NSAIDs) target pri
121 racted attention due to prior conjugation to nonsteroidal anti-inflammatory drugs (NSAIDs) to access
122                               The ability of nonsteroidal anti-inflammatory drugs (NSAIDs) to inhibit
123 d that acute respiratory infection (ARI) and nonsteroidal anti-inflammatory drugs (NSAIDs) use could
124                    Topical steroids and oral nonsteroidal anti-inflammatory drugs (NSAIDs) were used
125 ials evaluating the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) when used
126  back, musculoskeletal injuries with topical nonsteroidal anti-inflammatory drugs (NSAIDs) with or wi
127                                   The use of nonsteroidal anti-inflammatory drugs (NSAIDs) with oral
128 e placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corti
129 e placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corti
130 e of proton pump inhibitors (PPIs), aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selec
131                      Oxicams are widely used nonsteroidal anti-inflammatory drugs (NSAIDs), but littl
132 ribute to enteropathy associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs), but there
133 g modes to equine serum albumin (ESA) of two nonsteroidal anti-inflammatory drugs (NSAIDs), diclofena
134 eview the recent literature on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocort
135 undreds of millions of people worldwide take nonsteroidal anti-inflammatory drugs (NSAIDs), often in
136 ends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchi
137                                              Nonsteroidal anti-inflammatory drugs (NSAIDs), the medic
138 ve been evaluated for prophylaxis, including nonsteroidal anti-inflammatory drugs (NSAIDs), which are
139 arin with antiplatelet drugs or nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), which fur
140 nisms different from those of agents such as nonsteroidal anti-inflammatory drugs (NSAIDs).
141 ith acute sinusitis compared with placebo or nonsteroidal anti-inflammatory drugs (NSAIDs)?
142 cantly decrease risks for SP included use of nonsteroidal anti-inflammatory drugs (RR, 0.77; 95% CI,
143 antihypertensives, 4 diabetes medications, 2 nonsteroidal anti-inflammatory drugs [NSAIDs] or aspirin
144 hort-term exposure to SSRIs, as is done with nonsteroidal anti-inflammatory drugs and aspirin.
145                    Some COX inhibitors (i.e. nonsteroidal anti-inflammatory drugs and coxibs) and com
146                                 Accordingly, nonsteroidal anti-inflammatory drugs and NADPH oxidase i
147  treated with potassium-sparing diuretics or nonsteroidal anti-inflammatory drugs and oral potassium
148  aged 65 years or older, lack of exposure to nonsteroidal anti-inflammatory drugs and statins.
149 providing access to a variety of enantiopure nonsteroidal anti-inflammatory drugs and to alpha-amino
150 hol and smoking and taking analgesic agents (nonsteroidal anti-inflammatory drugs and weak opioids su
151             Low-molecular-weight heparin and nonsteroidal anti-inflammatory drugs are associated with
152                                         Oral nonsteroidal anti-inflammatory drugs are not recommended
153 should consider pharmacologic treatment with nonsteroidal anti-inflammatory drugs as first-line thera
154 employment status, and use of analgesics and nonsteroidal anti-inflammatory drugs at 1 and 12 months.
155 r array is able to differentiate six typical nonsteroidal anti-inflammatory drugs at concentrations o
156 ted in the effluent exposome of fish, 6 were nonsteroidal anti-inflammatory drugs but with plasma con
157 hen was ineffective for acute low back pain, nonsteroidal anti-inflammatory drugs had smaller benefit
158 rmance in semiquantitative identification of nonsteroidal anti-inflammatory drugs has been investigat
159  trials (RCTs) showed that oral steroids and nonsteroidal anti-inflammatory drugs have similar analge
160 tended to arylpropionic acids (including the nonsteroidal anti-inflammatory drugs ibuprofen and flurb
161 advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention a
162                     Reactions to aspirin and nonsteroidal anti-inflammatory drugs in patients with as
163                                              Nonsteroidal anti-inflammatory drugs interfere with the
164                                              Nonsteroidal anti-inflammatory drugs may impair wound he
165 ting that both ionized and neutral states of nonsteroidal anti-inflammatory drugs must be considered
166 BF4)3 and [Ru(NH3)5(L)](BF4)3 containing the nonsteroidal anti-inflammatory drugs nicotinic acid (Hni
167 sired, clinicians and patients should select nonsteroidal anti-inflammatory drugs or skeletal muscle
168 lls with pharmacological inhibitors, such as nonsteroidal anti-inflammatory drugs or small interferin
169 ts include oral contraceptives combined with nonsteroidal anti-inflammatory drugs or surgery to remov
170 ctures (OR, 2.65; 95% CI, 2.34-2.99), use of nonsteroidal anti-inflammatory drugs plus opioids (OR, 1
171                 Placebo-controlled trials of nonsteroidal anti-inflammatory drugs selective for inhib
172 to cause cardiovascular adverse effects than nonsteroidal anti-inflammatory drugs specific for inhibi
173 estinal ulcers are common adverse effects of nonsteroidal anti-inflammatory drugs such as acetylsalic
174                                              Nonsteroidal anti-inflammatory drugs such as sulindac in
175                                   The use of nonsteroidal anti-inflammatory drugs that inhibit cycloo
176                                              Nonsteroidal anti-inflammatory drugs use during ARI epis
177                                              Nonsteroidal anti-inflammatory drugs use during ARI was
178  in PBMCs, and supplementation of cells with nonsteroidal anti-inflammatory drugs was able to restore
179       Subjects with asthma hypersensitive to nonsteroidal anti-inflammatory drugs were compared with
180                  Eyes receiving prophylactic nonsteroidal anti-inflammatory drugs were excluded.
181 rt A) or unspecified (cohort B) reactions to nonsteroidal anti-inflammatory drugs were identified as
182 , decreased hematocrit, aspirin therapy, and nonsteroidal anti-inflammatory drugs were independently
183 UV filters, personal sunscreen products, and nonsteroidal anti-inflammatory drugs were seen in both g
184 hese differential effects were ignored, oral nonsteroidal anti-inflammatory drugs were superior.
185 lofenac is one of the most widely prescribed nonsteroidal anti-inflammatory drugs worldwide.
186  (age, sex, smoking, body mass index, use of nonsteroidal anti-inflammatory drugs) and symptoms of ga
187 s), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs), and adjustments t
188 ions (statins, aspirin, corticosteroids, and nonsteroidal anti-inflammatory drugs), with ulcerated pr
189 rials ranged from 9 (benzodiazepines) to 70 (nonsteroidal anti-inflammatory drugs).
190 g unnecessary medications such as aspirin or nonsteroidal anti-inflammatory drugs).
191 ry reactions to cyclooxygenase-1 inhibitors (nonsteroidal anti-inflammatory drugs).
192 the injection, 14% administer post operative nonsteroidal anti-inflammatory drugs, 28% administer pos
193 asm after the ingestion of aspirin and other nonsteroidal anti-inflammatory drugs, a disorder termed
194      These patients are usually treated with nonsteroidal anti-inflammatory drugs, acetaminophen, opi
195 roxychloroquine, intravenous immunoglobulin, nonsteroidal anti-inflammatory drugs, and cyclosporine,
196  other antihypertensives, aspirin, steroids, nonsteroidal anti-inflammatory drugs, Charlson Comorbidi
197 -opioid interventions such as acetaminophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 i
198 -opioid interventions such as acetaminophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 i
199  is inhibited by ACA as well as the fenamate nonsteroidal anti-inflammatory drugs, flufenamate and ni
200                 Preadmission use of statins, nonsteroidal anti-inflammatory drugs, glucocorticoids, o
201 flammatory drugs such as corticosteroids and nonsteroidal anti-inflammatory drugs, often accompanied
202 casionally after the intake of drugs such as nonsteroidal anti-inflammatory drugs, opioids and drugs
203 h DILI (due to acetaminophen, phenprocoumon, nonsteroidal anti-inflammatory drugs, or autoimmune hepa
204 ion single-agent or combined use of statins, nonsteroidal anti-inflammatory drugs, or glucocorticoids
205  Intra-articular treatments were superior to nonsteroidal anti-inflammatory drugs, possibly because o
206  (solid or liquid), and potential cofactors (nonsteroidal anti-inflammatory drugs, protonic pump inhi
207 ave been studied include aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, statins, agents th
208 h-sensitivity C-reactive protein, and use of nonsteroidal anti-inflammatory drugs, statins, and multi
209 ncer, and they are the molecular targets for nonsteroidal anti-inflammatory drugs, which are among th
210                                              Nonsteroidal anti-inflammatory drugs-induced urticaria/a
211 with short courses of oral contraceptives or nonsteroidal anti-inflammatory drugs.
212 Aryl esters represent an important family of nonsteroidal anti-inflammatory drugs.
213  mPGES-1 inhibitors as a safe alternative to nonsteroidal anti-inflammatory drugs.
214 so demonstrates the synthesis of a number of nonsteroidal anti-inflammatory drugs.
215 esult from the now worldwide availability of nonsteroidal anti-inflammatory drugs.
216 iguanides, sulfonylureas, aspirin, and other nonsteroidal anti-inflammatory drugs.
217 arallel samples were stimulated with related nonsteroidal anti-inflammatory drugs.
218 ion, and prophylaxis against ulceration from nonsteroidal anti-inflammatory drugs.
219 dified by factors such as smoking and use of nonsteroidal anti-inflammatory drugs.
220 vity reactions to beta-lactams, aspirin, and nonsteroidal anti-inflammatory drugs; however, the clini
221 atinocytes, and ACHP is an effective topical nonsteroidal anti-inflammatory in mice.
222 eated postoperatively with topical steroids, nonsteroidal anti-inflammatory medications (NSAIDs), or
223  that was not responsive to over-the-counter nonsteroidal anti-inflammatory medications.
224 ation of two therapeutic drugs, benzydamine (nonsteroidal anti-inflammatory) and tamoxifen (antiestro
225 either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group).
226                              Bicalutamide, a nonsteroidal antiandrogen, is widely used to treat men w
227 tion of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of sm
228           Most of the commercially available nonsteroidal antiandrogens show a common scaffold consis
229  element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowe
230 logically active substances (antibacterials, nonsteroidal antiinflammatories, antiseptics, antiepilep
231 The present study compared the effect of the nonsteroidal antiinflammatory drug (NSAID) diclofenac, w
232 estinal damage in zebrafish larvae using the nonsteroidal antiinflammatory drug (NSAID) Glafenine.
233            In the present study, sulindac, a nonsteroidal antiinflammatory drug (NSAID), was tested f
234 indings are potentially game-changing in the nonsteroidal antiinflammatory drug arena.
235 3 effects to blockade by two analgesics (the nonsteroidal antiinflammatory drug ketoprofen and the mu
236 but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or reso
237                                     Aspirin, nonsteroidal antiinflammatory drugs (NSAID), and acetami
238                            Among nonusers of nonsteroidal antiinflammatory drugs (NSAIDs) (Pinteracti
239                                     Although nonsteroidal antiinflammatory drugs (NSAIDs) in general
240                 The cardiovascular safety of nonsteroidal antiinflammatory drugs (NSAIDs) may be infl
241 of nine measures of high-risk prescribing of nonsteroidal antiinflammatory drugs (NSAIDs) or selected
242                            Acid suppression, nonsteroidal antiinflammatory drugs (NSAIDs), and statin
243  of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains un
244 nd is the therapeutic target for widely used nonsteroidal antiinflammatory drugs (NSAIDs).
245 atechins (naturally occurring flavonols) and nonsteroidal antiinflammatory drugs (NSAIDs).
246  as weight (kg)/height (m)2), never-users of nonsteroidal antiinflammatory drugs, and those with lowe
247                                              Nonsteroidal antiinflammatory drugs, including ibuprofen
248  mild pain in the thyroid) can be handled by nonsteroidal antiinflammatory drugs.
249 d arthritis (RA) and its response to chronic nonsteroidal antiinflammatory drugs.
250 looxygenase 2 inhibitors versus nonselective nonsteroidal antiinflammatory medications in 6-month gas
251           Interestingly, we now identified a nonsteroidal antiinflammatory selective GR agonist (SEGR
252 e small chemical changes in the structure of nonsteroidal AR ligands determine the pharmacological re
253       This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neit
254  reported in the accompanying paper that the nonsteroidal compound CpdX as well as its deuterated for
255              We previously reported that the nonsteroidal compound CpdX, which was initially characte
256 ding-capacity assays, we report here how two nonsteroidal compounds bind to human SHBG, and how they
257          Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated.
258 ent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through mic
259 methyl group was designed and synthesized as nonsteroidal CYP19 aromatase inhibitors.
260  Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer p
261 rapeutic agents (nonparticulate steroids and nonsteroidal drugs alike).
262 ver some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical
263  efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients wi
264 e-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are d
265   Seven-day treatment with inhalation of the nonsteroidal glucocorticoid receptor agonist AZD5423 eff
266        We evaluated the effect of an inhaled nonsteroidal glucocorticoid receptor agonist, AZD5423, o
267 ta[h]quinolin-3-one 3d (QCA-1093) as a novel nonsteroidal glucocorticoid receptor antagonist.
268 prednisolone and also by compound A, a novel nonsteroidal glucocorticoid receptor ligand.
269 sonicotinamides exemplified by compound 3 as nonsteroidal GPBAR1 agonists.
270 sign and pharmacology of clinically relevant nonsteroidal GR antagonists that may have greater select
271 refined classic GCs or a novel generation of nonsteroidal GR-targeting molecules, to meet the increas
272 ective and efficient method of preparing the nonsteroidal, inhaled selective glucocorticoid receptor
273 f the cardioactive terpenoid (+)-cassaine, a nonsteroidal inhibitor of Na(+)-K(+)-ATPase.
274 exes with estrone and with the first potent, nonsteroidal inhibitor.
275 dy was to identify and optimize 17beta-HSD14 nonsteroidal inhibitors as well as to disclose their str
276                  These findings indicate how nonsteroidal ligands of SHBG maybe designed to modulate
277 gested opportunities for the design of other nonsteroidal ligands of SHBG.
278 C-ring, alone and in combination, as well as nonsteroidal mimics provided numerous potent VDR agonist
279 ated whether the administration of the novel nonsteroidal mineralocorticoid receptor (MR) antagonist
280                            A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists
281                          (-)-Finerenone is a nonsteroidal mineralocorticoid receptor antagonist curre
282  modifications were efficiently prevented by nonsteroidal MR antagonism.
283 s effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher t
284  restricted to steroidal MR antagonists as a nonsteroidal MR antagonist failed to reduced blood press
285                     MR blockade by the novel nonsteroidal MR antagonist, finerenone, or genetic delet
286                          Finerenone, a novel nonsteroidal MR antagonist, is presently being evaluated
287                 Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treat
288   Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibito
289                      However, a more direct, nonsteroidal role of LH mediating the spermiogenic pathw
290 reports have described the increasing use of nonsteroidal selective androgen receptor modulators, whi
291 gic evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and
292                           A class of potent, nonsteroidal, selective indazole ether-based glucocortic
293                                Finerenone, a nonsteroidal, selective mineralocorticoid receptor antag
294  Kidney Disease) evaluated the effect of the nonsteroidal, selective mineralocorticoid receptor antag
295 ting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials.
296  to identify bile acid mimetics we uncovered nonsteroidal small molecule scaffolds that bind and inhi
297 ification and characterization of AZD9496, a nonsteroidal small-molecule inhibitor of ERalpha, which
298 tory activities of a series of steroidal and nonsteroidal sulfamate derivatives against CA IX in comp
299  fundamental need to identify nonestrogen or nonsteroidal targets for the treatment of endometriosis.
300  basis to formulate long-term nonestrogen or nonsteroidal therapy for endometriosis.

 
Page Top